Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumanta Kumar Pal

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Maturitas|July 28, 2009
Triple-negative breast cancer: novel therapies and new directionsSumanta Kumar Pal, Joanne Mortimer
Women'S Health (London, England)|April 28, 2009
Adjuvant systemic therapy for older adults with early-stage breast cancerSumanta Kumar Pal, Joanne Mortimer
Reviews in Endocrine & Metabolic Disorders|September 28, 2007
HER2 targeted therapy in breast cancer...beyond HerceptinSumanta Kumar Pal, Mark Pegram
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Impact of age, sex, and comorbidity on cancer therapy and disease progressionSumanta Kumar Pal, Arti Hurria
Maturitas|November 25, 2010
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancerSumanta Kumar Pal, Oliver Sartor
Seminars in Oncology|August 8, 2006
Targeting HER2 EpitopesSumanta Kumar Pal, Mark Pegram
Asian Journal of Andrology|May 24, 2011
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancerSumanta Kumar Pal, Oliver Sartor
Women'S Health (London, England)|August 26, 2009
Adjuvant chemotherapy for older adults with breast cancer: making the standard a standardSumanta Kumar Pal, Joanne Mortimer
Anti-Cancer Drugs|April 23, 2005
Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapySumanta Kumar Pal, Mark Pegram
Clinical Medicine Insights. Oncology|August 17, 2010
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR InhibitorsSumanta Kumar Pal, Robert A Figlin
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Maturitas|July 28, 2009
Triple-negative breast cancer: novel therapies and new directionsSumanta Kumar Pal, Joanne Mortimer
Women'S Health (London, England)|April 28, 2009
Adjuvant systemic therapy for older adults with early-stage breast cancerSumanta Kumar Pal, Joanne Mortimer
Reviews in Endocrine & Metabolic Disorders|September 28, 2007
HER2 targeted therapy in breast cancer...beyond HerceptinSumanta Kumar Pal, Mark Pegram
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Impact of age, sex, and comorbidity on cancer therapy and disease progressionSumanta Kumar Pal, Arti Hurria
Maturitas|November 25, 2010
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancerSumanta Kumar Pal, Oliver Sartor
Seminars in Oncology|August 8, 2006
Targeting HER2 EpitopesSumanta Kumar Pal, Mark Pegram
Asian Journal of Andrology|May 24, 2011
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancerSumanta Kumar Pal, Oliver Sartor
Women'S Health (London, England)|August 26, 2009
Adjuvant chemotherapy for older adults with breast cancer: making the standard a standardSumanta Kumar Pal, Joanne Mortimer
Anti-Cancer Drugs|April 23, 2005
Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapySumanta Kumar Pal, Mark Pegram
Clinical Medicine Insights. Oncology|August 17, 2010
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR InhibitorsSumanta Kumar Pal, Robert A Figlin
Pageof 10